Helpline
0800 121 8721
Email us
Fundraising Donate

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

21 Jun 2019

Tags
brain metastases ipilimumab nivolumab Opdivo renal cell carcinoma Yervoy
Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month.

Read more in Cancer Therapy Advisor here

Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

22 Jan 2025

Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer

Read More

20 Jan 2025

Promising new combination therapy for advanced kidney cancer

Read More

9 Jan 2025

NHS England's Elective Care Reform Plan

Read More

8 Jan 2025

FDA approves injectable form of nivolumab

Read More

6 Jan 2025

NHS Help Us, Help You campaign

Read More

20 Dec 2024

NHS National Cancer Patient Experience Survey

Read More

9 Dec 2024

Promising new immunotherapy combination for advanced kidney cancer

Read More

5 Dec 2024

New treatment for pretreated advanced kidney cancer shows promise

Read More

18 Nov 2024

Cancer waiting times - latest updates

Read More

15 Nov 2024

The Big Cancer52 Conversation

Read More

12 Nov 2024

How to manage side effects to cabozantinib and nivolumab

Read More

1 Nov 2024

Government commits to a 'stand-alone cancer strategy'

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib cabozantinib Sutent progression-free survival NHS England kidney cancer biomarkers ipilimumab Cabometyx pembrolizumab COVID-19 axitinib cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus Yervoy risk factors adjuvant therapy Keytruda metastases targeted therapy everolimus papillary RCC biological markers Afinitor cancer outcomes ASCO first-line treatment NICE

Archives

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

X-Twitter
Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top